$Safety and effectiveness of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure with preserved ejection fraction (HFPEF) – ‘ARNI-preserved’ study$
Código QR

Código QR

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure with preserved ejection fraction (HFPEF) – ‘ARNI-preserved’ study

Guardado en:

Detalles Bibliográficos
Autores principales:	Pankaj Jariwala, Kartik Jadhav
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Surgery RD1-811 Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/078ac2117a414bc59d6ea8d42501fd27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
por: Pankaj Jariwala, et al.
Publicado: (2021)

Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
por: Berkay Ekici, et al.
Publicado: (2021)

Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Hyue Mee Kim, et al.
Publicado: (2021)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
por: M. A. Manukyan, et al.
Publicado: (2021)

Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations
por: Dzhioeva O, et al.
Publicado: (2020)

Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study
por: Ravi B. Patel, et al.
Publicado: (2021)

Prognostic significance of dipstick proteinuria in heart failure with preserved ejection fraction: insight from the PURSUIT-HFpEF registry
por: Tetsuhisa Kitamura, et al.
Publicado: (2021)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: Veronika Zach, et al.
Publicado: (2020)

Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction
por: Pankaj Garg, et al.
Publicado: (2021)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Steffen Pabel, et al.
Publicado: (2021)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Hidekatsu Fukuta
Publicado: (2020)

Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction.
por: Jae Hyung Cho, et al.
Publicado: (2021)

A profile of heart failure with preserved ejection fraction in a teaching institute
por: Gaurav Aggarwal, et al.
Publicado: (2021)

ARNI, LBBB, COVID-19 and various other topics
por: Çetin Erol
Publicado: (2021)

Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
por: Sebastian Rosch, et al.
Publicado: (2020)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
por: Sebastiaan HC Klaassen, et al.
Publicado: (2020)

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis.
por: Feng Liu, et al.
Publicado: (2014)

Remote Hind-Limb Ischemia Mechanism of Preserved Ejection Fraction During Heart Failure
por: Rubens P. Homme, et al.
Publicado: (2021)

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
por: M. O.E. Irhuma, et al.
Publicado: (2016)

Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
por: Wan Ting Tay, et al.
Publicado: (2021)

A study of association between heart failure with preserved ejection fraction with hypertension and diabetes mellitus
por: Swapan Sarkar, et al.
Publicado: (2021)

Association of serum total bilirubin levels with diastolic dysfunction in heart failure with preserved ejection fraction
por: Zheng,Huan, et al.
Publicado: (2014)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Antoni Bayes-Genis, et al.
Publicado: (2021)

Heart failure clinical care analysis uncovers risk reduction opportunities for preserved ejection fraction subtype
por: Rebecca T. Levinson, et al.
Publicado: (2021)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Mackram F Eleid, et al.
Publicado: (2021)

Machine learning based diagnosis of heart failure with preserved ejection fraction among South Asian patients
por: Ananya Achanta, et al.
Publicado: (2021)

The Prognostic Value of Lung Ultrasound in Patients With Newly Diagnosed Heart Failure With Preserved Ejection Fraction in the Ambulatory Setting
por: Blanka Morvai-Illés, et al.
Publicado: (2021)

The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction
por: Agata Bielecka-Dabrowa, et al.
Publicado: (2017)

Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
por: Giuseppe MC Rosano, et al.
Publicado: (2019)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
por: Davide Stolfo, et al.
Publicado: (2019)

Association of free fatty acid binding protein with central aortic stiffness, myocardial dysfunction and preserved ejection fraction heart failure
por: Chih-Hsuan Yen, et al.
Publicado: (2021)

Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction
por: Gabriele G. Schiattarella, et al.
Publicado: (2021)

Approaching Higher Dimension Imaging Data Using Cluster-Based Hierarchical Modeling in Patients with Heart Failure Preserved Ejection Fraction
por: Yukari Kobayashi, et al.
Publicado: (2019)

Relevance of Neutrophil Neprilysin in Heart Failure
por: Suriya Prausmüller, et al.
Publicado: (2021)

The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
por: Osama A. Amin, et al.
Publicado: (2021)

β-Hydroxybutyrate Mitigated Heart Failure with Preserved Ejection Fraction by Increasing Treg Cells via Nox2/GSK-3β
por: Liao S, et al.
Publicado: (2021)

Deep Learning Predicts Heart Failure With Preserved, Mid-Range, and Reduced Left Ventricular Ejection Fraction From Patient Clinical Profiles
por: Mohanad Alkhodari, et al.
Publicado: (2021)

Left atrial pressure overload and prognosis in elderly patients with heart failure and preserved ejection fraction: a prospective multicenter observational study
por: Shinichiro Suna, et al.
Publicado: (2021)

Clinical course and outcomes of chronic heart failure with preserved left ventricular ejection fraction in concomitant overweight and obesity with comorbid atrial fibrillation
por: P. P. Bidzilya, et al.
Publicado: (2021)

Link Between Synovial and Myocardial Inflammation: Conceptual Framework to Explain the Pathogenesis of Heart Failure with Preserved Ejection Fraction in Patients with Systemic Rheumatic Diseases
por: Milton Packer
Publicado: (2020)